Sei Investments Co. Acquires 7,080 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sei Investments Co. lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 527,686 shares of the medical equipment provider’s stock after acquiring an additional 7,080 shares during the period. Sei Investments Co.’s holdings in Intuitive Surgical were worth $234,734,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Capital Research Global Investors purchased a new stake in Intuitive Surgical during the 1st quarter worth about $374,390,000. Coatue Management LLC lifted its holdings in shares of Intuitive Surgical by 65.7% in the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock worth $439,106,000 after buying an additional 516,054 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares during the period. Edgewood Management LLC grew its stake in Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Intuitive Surgical by 51.2% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after acquiring an additional 302,382 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 0.8 %

NASDAQ ISRG opened at $486.20 on Friday. The company has a 50-day simple moving average of $468.01 and a two-hundred day simple moving average of $424.86. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18. The firm has a market cap of $172.46 billion, a price-to-earnings ratio of 87.76, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the business posted $1.18 EPS. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on ISRG. Stifel Nicolaus raised their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Morgan Stanley lifted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Citigroup upped their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Barclays lifted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.